A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...

Whereas interactive social media marketing is widespread in many industries, including healthcare, it seems that both FDA and the drug industry are playing catch-up. According to Jonathan Richman ...

The company looked at around 14,000 messages from more than 380 pharma brands to pick up patterns in the recall and effectiveness of marketing messaging ... stages in the drug launch life cycle ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the treatment of Alzheimer's disease.

Compounded drugs, and particularly off-brand versions ... the spokesperson told Fierce Pharma Marketing, “We are referring to both compounded products and any products that are marketed like ...

We analysed new anticancer drug indications approved by the FDA and EMA between 2020 and 2023 using the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale quality-of-life ...

The growing prevalence of ultrahigh-cost drugs under development is prompting health systems nationwide to rethink strategies ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...